secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001641172-25-020043
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA announces peer-reviewed publication validating second-gen ateganosine prodrugs
--------------------------------------------------------------------------------

- Data published in Nucleic Acids Research (Vol. 53, Issue 12, June 26, 2025) on novel telomere-targeting dinucleotide prodrugs.
- Lead candidates MAIA-2022-12 and MAIA-2021-20 showed strongest in vivo anticancer efficacy and immune-memory responses.
- Combination with immune checkpoint inhibitor yielded significantly lower IC50 and superior efficacy vs monotherapy.
- Company plans to advance one candidate into human clinical trials after completing GLP-toxicity studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225020043/0001641172-25-020043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225020043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-020043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer